Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$8.3 million.

  • Anika Therapeutics' Cash from Investing Activities rose 4.63% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 78.50%. This contributed to the annual value of -$8.3 million for FY2024, which is 53.57% down from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Cash from Investing Activities is -$8.3 million, which was down 53.57% from -$5.4 million recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Cash from Investing Activities peaked at -$3.1 million during FY2021, and registered a low of -$71.3 million during FY2020.
  • Its 3-year average for Cash from Investing Activities is -$7.1 million, with a median of -$7.5 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 279.55% in 2020, then surged by 95.62% in 2021.
  • Over the past 5 years, Anika Therapeutics' Cash from Investing Activities (Yearly) stood at -$71.3 million in 2020, then skyrocketed by 95.62% to -$3.1 million in 2021, then tumbled by 140.09% to -$7.5 million in 2022, then increased by 27.50% to -$5.4 million in 2023, then slumped by 53.57% to -$8.3 million in 2024.